Philadelphia, Pennsylvania--(Newsfile Corp. - December 19, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https ...

集体诉讼事件 - 一家全国性原告律师事务所Berger Montague PC宣布，已代表在2025年2月21日至2025年8月28日期间购买Telix Pharmaceuticals Ltd证券的投资者，对该公司提起集体诉讼 [1] 公司业务与指控 - Telix Pharmaceuticals Ltd是一家总部位于澳大利亚墨尔本的生物制药公司，致力于开发诊断和治疗用放射性药物产品 [2] - 诉讼指控被告在集体诉讼期间做出了虚假或误导性陈述，和/或未能披露公司夸大了其前列腺癌治疗候选药物的进展，并夸大了其供应链及合作伙伴的质量 [3] - 据称，关于公司业务、运营和前景的陈述是虚假的、误导性的或缺乏合理依据的，当公司业务的真实状况被公开后，投资者遭受了重大损失 [3] 律师事务所背景 - Berger Montague是一家专注于复杂民事诉讼、集体诉讼和美国各地联邦及州法院大规模侵权案件的知名律师事务所 [5] - 该律所在2025年仅审判后判决的金额就超过24亿美元，并在复杂诉讼、反垄断、消费者保护、缺陷产品、环境法、就业法、证券和举报人案件等领域处于领先地位 [5] - 在过去55年多的时间里，该律所在开创先例的案件中发挥了主导作用，并已为其客户及所代表的集体追回了超过500亿美元 [5]

案件概述 - 罗森律师事务所提醒在2025年2月21日至2025年8月28日期间购买Telix Pharmaceuticals Ltd (NASDAQ: TLX) 证券的投资者 关于2026年1月9日的重要首席原告截止日期 [1] - 一项针对Telix的证券集体诉讼已经提起 投资者可能有权通过风险代理收费安排获得赔偿 而无需支付任何自付费用 [2][3] 诉讼指控详情 - 指控被告在整个集体诉讼期间做出了重大虚假和/或误导性陈述 和/或未能披露 [5] - 具体指控包括 被告严重夸大了Telix在前列腺癌治疗候选药物方面取得的进展 [5] - 被告严重夸大了Telix的供应链及合作伙伴的质量 [5] - 因此 被告关于Telix业务 运营和前景的陈述在所有相关时间均存在重大虚假和误导性 和/或缺乏合理依据 [5] - 诉讼称 当真实情况进入市场时 投资者遭受了损失 [5] 律师事务所信息 - 罗森律师事务所是一家全球投资者权益律师事务所 专注于证券集体诉讼和股东衍生诉讼 [4] - 该所曾达成针对中国公司的史上最大证券集体诉讼和解 并在2017年被ISS证券集体诉讼服务评为和解数量第一 [4] - 自2013年以来 该所每年排名前四 已为投资者追回数亿美元 仅在2019年就为投资者确保了超过4.38亿美元 [4]

DroneShield Limited lost its momentum on Wednesday, the day after finding a place in the top gainers on the This comes a day after the Australian share market witnessed a decline as it ended the day on Tuesday (December 16, 2025) with the S&P/ASX 200 closing on the lower side, dropping 36.10 points, or 0.42%, to 8,598.90.ASX 200: Top gainers and losersOn the S&P/ASX 200, several stocks recorded notable gains and declines. Among the top performers, IGO Limited (IGO) led the board with a last price of $7.690 ...

针对Telix Pharmaceuticals Ltd的集体诉讼通知 - 罗森律师事务所提醒在2025年2月21日至2025年8月28日期间购买Telix Pharmaceuticals Ltd证券的投资者注意2026年1月9日的首席原告截止日期 [1] - 投资者可能有权通过风险代理收费安排获得赔偿而无需支付任何自付费用 [2] - 投资者可通过指定网站或电话联系以加入集体诉讼或申请担任首席原告 [3][6] 罗森律师事务所背景 - 该律所专注于证券集体诉讼和股东衍生诉讼在全球代表投资者 [4] - 该律所曾达成针对中国公司的史上最大证券集体诉讼和解并在2017年因和解数量被ISS证券集体诉讼服务评为第一自2013年以来每年排名前四 [4] - 该律所已为投资者挽回数亿美元其中2019年单年为投资者确保了超过4.38亿美元 [4] 诉讼指控详情 - 指控被告在集体诉讼期间做出了重大虚假和/或误导性陈述和/或未能披露相关信息 [5] - 具体指控包括被告在Telix前列腺癌治疗候选药物的进展方面存在重大夸大 [5] - 具体指控包括被告在Telix供应链及合作伙伴的质量方面存在重大夸大 [5] - 指控结果导致被告关于Telix业务运营和前景的陈述在所有相关时间均存在重大虚假和误导性和/或缺乏合理依据 [5]

SAN DIEGO--(BUSINESS WIRE)---- $TLX #Telix--Robbins LLP: Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. What is the class period? February 21, 2025 - August 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or acquired Telix securities during the class p ...

We recently published 7 Best ASX Stocks to Buy Right Now.  Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the best ASX stocks. Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biotechnology company developing treatments for ailments such as prostate and kidney cancer. The firm’s prostate cancer therapy candidate TLX591 is currently in a phase three study. On this front, Telix Pharmaceuticals Limited (NASDAQ:TLX) shared important news on December 8th when it announced that it had dosed the first patie ...

PHILADELPHIA, Dec. 15, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...